ES2651019T3 - Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90 - Google Patents

Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90 Download PDF

Info

Publication number
ES2651019T3
ES2651019T3 ES07811232.3T ES07811232T ES2651019T3 ES 2651019 T3 ES2651019 T3 ES 2651019T3 ES 07811232 T ES07811232 T ES 07811232T ES 2651019 T3 ES2651019 T3 ES 2651019T3
Authority
ES
Spain
Prior art keywords
compound
disease
equiv
acid
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07811232.3T
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Winssinger
Sofia Barluenga
Martin Karplus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Strasbourg filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2651019T3 publication Critical patent/ES2651019T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
ES07811232.3T 2006-08-11 2007-08-10 Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90 Active ES2651019T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83715406P 2006-08-11 2006-08-11
US837154P 2006-08-11
US85873106P 2006-11-13 2006-11-13
US858731P 2006-11-13
PCT/US2007/017754 WO2008021213A1 (en) 2006-08-11 2007-08-10 Macrocyclic compounds useful as inhibitors of kinases and hsp90

Publications (1)

Publication Number Publication Date
ES2651019T3 true ES2651019T3 (es) 2018-01-23

Family

ID=39082315

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07811232.3T Active ES2651019T3 (es) 2006-08-11 2007-08-10 Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90

Country Status (7)

Country Link
US (2) US8067412B2 (en:Method)
EP (1) EP2136799B1 (en:Method)
JP (1) JP5465006B2 (en:Method)
CN (2) CN103539769B (en:Method)
CA (1) CA2696021C (en:Method)
ES (1) ES2651019T3 (en:Method)
WO (1) WO2008021213A1 (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8067412B2 (en) 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP2231634B1 (en) 2007-12-07 2016-05-11 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
MX2010007755A (es) 2008-01-15 2010-12-21 Univ Strasbourg Sintesis de lactonas de acido resorcilico utiles como agentes terapeuticos.
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
CA2808866A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
KR20140021520A (ko) * 2010-10-22 2014-02-20 위니베르시떼 드 스트라스부르 Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트
WO2013062923A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
WO2016196256A2 (en) * 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
US3239346A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
FR96016E (fr) * 1966-06-29 1972-05-19 Commercial Solvents Corp Composé utilisable comme supplément alimentaire pour les animaux.
US3453367A (en) * 1966-06-29 1969-07-01 Commercial Solvents Corp Methods for treating inflammation with estrogenic compounds
NL131183C (en:Method) * 1966-12-13
US3758511A (en) * 1967-01-18 1973-09-11 Merck & Co Inc Preparation of d,1-zearalenones
US3551454A (en) * 1967-07-26 1970-12-29 Merck & Co Inc Preparation of optically active (-)-zearalenone and intermediates therefor
US3586701A (en) * 1967-08-24 1971-06-22 Commercial Solvents Corp Norzearalane and its production
US3887583A (en) * 1968-05-15 1975-06-03 Commercial Solvents Corp Products and process
US3591608A (en) * 1968-11-15 1971-07-06 Ayerst Mckenna & Harrison Macrocyclic ketolactones
US3621036A (en) * 1969-02-27 1971-11-16 Merck & Co Inc Derivatives of zearalane
US3704249A (en) * 1969-05-01 1972-11-28 Merck & Co Inc Synthesis of the biologically active diastereoisomer of (-) zearalanol
US3860616A (en) * 1969-05-01 1975-01-14 Merck & Co Inc Synthesis of d,1-zearalanol
BE757083A (fr) * 1970-02-16 1971-03-16 Commercial Solvents Corp Nouveaux produits a activite antibacterienne
BE757082A (fr) * 1970-02-16 1971-03-16 Commercial Solvents Corp Procede de preparation de nouveaux produits a activite antibacterienne
US3687982A (en) * 1971-03-09 1972-08-29 Commercial Solvents Corp Separation of mixed diastereoisomers of zearalanol
US3901922A (en) * 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanone and related compounds and intermediates useful in their synthesis
US3836544A (en) * 1972-04-25 1974-09-17 Commercial Solvents Corp Synthesis of zearalanes ii and related compounds and intermediates useful in the syntheses thereof
US3903115A (en) * 1972-04-25 1975-09-02 Commercial Solvents Corp Synthesis of zearalanes II and related compounds and intermediates useful in the syntheses thereof
US3810918A (en) * 1972-04-25 1974-05-14 Commercial Solvent Corp Synthesis of zearalanone
US3957825A (en) * 1972-04-25 1976-05-18 Commercial Solvents Corporation Process for synthesizing zearalanone and related compounds
US3901921A (en) * 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanes and related compounds and intermediates useful in the syntheses thereof
US3852307A (en) * 1972-04-25 1974-12-03 Commercial Solvents Corp Synthesis of zearalanone and related compounds
US3925423A (en) * 1974-01-22 1975-12-09 Commercial Solvents Corp Resorcyclic acid lactones and their production
US3965275A (en) * 1974-02-11 1976-06-22 Commercial Solvents Corporation Composition and method
US3954805A (en) * 1974-06-06 1976-05-04 Commercial Solvents Corporation Process for preparing zearalene type compounds
US4035504A (en) * 1975-05-12 1977-07-12 Imc Chemical Group, Inc. Method for treating cholesterolemia by administering resorcylic acid lactone derivatives
US4088658A (en) * 1976-11-04 1978-05-09 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4042602A (en) * 1976-11-04 1977-08-16 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4228079A (en) * 1978-10-30 1980-10-14 W. R. Grace & Co. Dialkoxy monorden derivatives
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
EP0248916A1 (en) * 1986-06-05 1987-12-16 C.R.C. Compagnia di Ricerca Chimica S.p.A. Method for separation of 3S,7R-3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one from its 3S,7S-diastereomer
US4751239A (en) * 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives
US4778821A (en) * 1987-07-15 1988-10-18 International Minerals & Chemical Corp. Method for controlling helmintic parasites
US4849447A (en) * 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
US4902711A (en) * 1988-01-19 1990-02-20 Pitman-Moore, Inc. 6' Carbamate esters of zearalanol and its derivatives
US5650430A (en) * 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
IE911915A1 (en) * 1990-06-06 1991-12-18 Sankyo Co Radicicol derivatives, their preparation and their¹anti-tumor activity
JPH06279279A (ja) 1993-03-26 1994-10-04 Tsumura & Co 血管新生阻害剤
JPH06298764A (ja) 1993-04-15 1994-10-25 Kyowa Hakko Kogyo Co Ltd 免疫抑制剤
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
WO1996033989A1 (en) * 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
US5710174A (en) * 1995-06-07 1998-01-20 Zymo Genetics, Inc. Factor XIIIA inhibitor
JPH09202781A (ja) 1996-01-25 1997-08-05 Sankyo Co Ltd ラディシコール誘導体
CN1211244A (zh) * 1996-10-25 1999-03-17 协和发酵工业株式会社 根赤壳菌素衍生物
JPH10265381A (ja) 1997-03-24 1998-10-06 Sankyo Co Ltd 血管再狭窄予防剤
WO1999055689A1 (en) 1998-04-24 1999-11-04 Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives
JP2002533389A (ja) * 1998-12-24 2002-10-08 ノーベーション ファーマシューティカルズ インコーポレーテッド ｍＲＮＡ安定性に影響する化合物およびそのための使用
JP2000236894A (ja) 1999-02-19 2000-09-05 Kyowa Hakko Kogyo Co Ltd ラディシコールの製造方法
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
AU2001278152C1 (en) * 2000-08-04 2009-02-05 Board Of Regents, The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
US6734209B2 (en) * 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
ES2354039T3 (es) 2000-08-18 2011-03-09 Millennium Pharmaceuticals, Inc. Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
DE60120427D1 (de) * 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
CA2426952C (en) * 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
US20030211469A1 (en) * 2001-07-16 2003-11-13 Lloyd Waxman Inhibiting hepatitis c virus processing and replication
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2003113183A (ja) * 2001-10-05 2003-04-18 Kyowa Hakko Kogyo Co Ltd リウマチ治療剤
EP1450784A4 (en) * 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
CA2468202A1 (en) * 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
AU2003224672B2 (en) * 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
CN1652743A (zh) * 2002-04-17 2005-08-10 大正制药株式会社 毛发生长补剂
AU2003264357A1 (en) * 2002-08-29 2004-04-30 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
US20060251574A1 (en) * 2002-12-12 2006-11-09 Adeela Kamal Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US20070004674A1 (en) * 2003-08-22 2007-01-04 Kyowa Hakko Kogyo Co. Ltd. Remedy for diseases associated with immunoglobulin gene translocation
US20080108694A1 (en) * 2003-12-19 2008-05-08 Samuel J Danishefsky Novel Macrocycles and Uses Thereof
WO2005105077A1 (en) * 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
WO2006119456A2 (en) * 2005-05-04 2006-11-09 University Of Vermont And State Agricultural College Methods and compositions for treating toxoplasma
US8067412B2 (en) 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90

Also Published As

Publication number Publication date
EP2136799A4 (en) 2010-10-27
CN101588799B (zh) 2013-09-11
EP2136799A1 (en) 2009-12-30
JP5465006B2 (ja) 2014-04-09
JP2010501478A (ja) 2010-01-21
CN103539769A (zh) 2014-01-29
US20120077775A1 (en) 2012-03-29
WO2008021213A1 (en) 2008-02-21
CN101588799A (zh) 2009-11-25
US20080146545A1 (en) 2008-06-19
CN103539769B (zh) 2016-03-16
EP2136799B1 (en) 2017-10-04
US8067412B2 (en) 2011-11-29
CA2696021A1 (en) 2008-02-21
CA2696021C (en) 2015-09-29
US8450305B2 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
ES2651019T3 (es) Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90
KR101835253B1 (ko) 치료제로서 유용한 레조르실산 락톤의 합성
CA2812320A1 (en) Pochoxime conjugates useful for the treatment of hsp90 related pathologies
CN102015673B (zh) 用作治疗剂的大环前药化合物
WO2008149244A2 (en) Compositions and methods comprising analogues of radicicol a
US20140135290A1 (en) Macrocyclic prodrug compounds useful as therapeutics
HK1151522B (en) Macrocyclic prodrug compounds useful as therapeutics